Effects of Oral Valiltramiprosate on Clinical Efficacy, Safety, and Brain Volume Outcomes in APOE4/4 Homozygotes with Early Alzheimer’s Disease (AD): Topline Results of the 78-week Phase 3 APOLLOE4 Trial

Severe ARIA Early after Donanemab Initiation Despite Eligible Baseline MRI

Reversal of Memory Loss Using Kisunla and Leqembi in Early AD and MCI due to AD in Community Cohort